0
0
The Upcoming Reclassification of Marijuana by the US Drug Enforcement Administration
The US Drug Enforcement Administration is preparing for a significant shift in federal policy by reclassifying marijuana to a lower-risk drug category. This move aligns with recommendations made by the US health department last year, signaling a potential change in how the federal government views the substance. The reclassification was first reported by the Associated Press on Tuesday afternoon and has been subsequently confirmed by various news outlets.
Current Classification and Proposed Change
Currently, the DEA categorizes marijuana as a Schedule 1 drug, alongside substances like LSD and heroin. Schedule 1 drugs are defined as having “no currently accepted medical use and a high potential for abuse.” The proposed reclassification would shift marijuana to a Schedule 3 drug, characterized by “a moderate to low potential for physical and psychological dependence.” This new category would place marijuana in line with substances such as ketamine, testosterone, and products containing less than 90 milligrams of codeine.
This potential reclassification acknowledges the medical benefits associated with marijuana and brings federal policy closer to the stance taken by many states. Presently, 38 states have legalized medical marijuana, reflecting a growing acceptance of the substance’s therapeutic value.
Scientific Research Implications
The reclassification of marijuana could have a significant impact on scientific research surrounding the effects of the substance. Many academic researchers rely on federal funding, which subjects them to strict regulations when studying Schedule 1 drugs. By lowering marijuana’s classification, researchers would gain greater access to conducting studies that have long been awaited.
Logistical Changes and Potential Timeline
If the reclassification goes through, approximately 15,000 dispensaries would need to register with the DEA, operating similarly to pharmacies with strict reporting requirements. Despite existing access to marijuana in many states, a Schedule 3 classification would bring continued regulation by the DEA.
While the exact timeline for this change remains uncertain, the DEA must receive approval from the White House Office of Management and Budget (OMB) before proceeding. Reports suggest that Attorney General Merrick Garland may submit the rescheduling to the OMB as early as Tuesday afternoon. Following this step, the DEA would initiate a public comment period before finalizing the rule.
The US Department of Justice has indicated that it is actively working on the rule but refrained from providing further details at this time.
Image/Photo credit: source url
